Perfusion MRI in the early clinical development of antivascular drugs: Decorations or decision making tools?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue SUPPL. 1, 2010, Pages

  Zweifel, Martin ^a   Padhani, Anwar R ^b  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Antiangiogenic agent; DCE MRI; Perfusion; Permeability; Phase I trial; Phase II trial; Vascular disrupting agent

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BIBF 1120; BIOLOGICAL MARKER; BRIVANIB ALANINATE; CDP 860; CEDIRANIB; CNTO 95; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; FOSBRETABULIN; GADOLINIUM CHELATE; INTETUMUMAB; MOTESANIB; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; SEMAXANIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 3; VATALANIB;

BLOOD FLOW; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; DOSE LIMITING TOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; KINETICS; LIVER CELL CARCINOMA; LIVER METASTASIS; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; MIXED TUMOR; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; TOXICITY TESTING; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD VESSELS; CONTRAST MEDIA; DECISION MAKING; DRUG DISCOVERY; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; NEOPLASMS;

EID: 77956265269     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1451-z     Document Type: Review

References (83)

1. JM Collins 2003 Functional imaging in phase I studies: decorations or decision making? J Clin Oncol 21 2807 2809 10.1200/JCO.2003.05.100 12807933
2. C Rüegg JY Meuwly R Driscoll P Werffeli K Zaman R Stupp 2003 The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials Curr Mol Med 3 673 691 10.2174/1566524033479410 14682490
3. RK Jain 2001 Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 987 989 10.1038/nm0901-987 1:CAS:528:DC%2BD3MXmvFOmsrc%3D 11533692
4. WS Kamoun CD Ley CT Farrar AM Duyverman J Lahdenranta DA Lacorre, et al. 2009 Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice J Clin Oncol 27 2542 2552 10.1200/JCO.2008.19.9356 1:CAS:528:DC%2BD1MXmvVOhsbY%3D 19332720
5. TT Batchelor AG Sorensen E di Tomaso WT Zhang DG Duda KS Cohen, et al. 2007 AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 83 95 10.1016/j.ccr.2006.11.021 1:CAS:528:DC%2BD2sXhtFClsLc%3D 17222792
6. M Oostendorp MJ Post WH Backes 2009 Vessel growth and function: depiction with contrast-enhanced MR imaging Radiology 251 317 335 10.1148/radiol. 2512080485 19401568
7. S Kety 1960 Measurement of local blood flow by the exchange of an inert, diffusible substance Methods Med Res 8 228 236
8. S Kety 1960 Blood-tissue exchange methods. Theory of blood-tissue exchange and its application to measurement of blood flow Methods Med Res 8 223 227
9. P Tofts G Brix D Buckley J Evelhoch E Henderson M Knopp, et al. 1999 Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols J Magn Reson Imaging 10 223 232 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S 1:STN:280:DyaK1Mvjsl2jtw%3D%3D 10508281
10. ID Wilkinson DA Jellineck D Levy FL Giesel CA Romanowski BA Miller, et al. 2006 Dexamethasone and enhancing solitary cerebral mass lesions: alterations in perfusion and blood-tumor barrier kinetics shown by magnetic resonance imaging Neurosurgery 58 640 646 10.1227/01.NEU.0000204873.68395.A0 16575327 discussion 640-6
11. JP O'Connor RA Carano AR Clamp J Ross CC Ho A Jackson, et al. 2009 Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging Clin Cancer Res 15 6674 6682 10.1158/1078-0432.CCR-09-0731 19861458
12. KJ Lankester RJ Maxwell RB Pedley JL Dearling UA Qureshi 2007 E, et al. Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down Int J Oncol 30 453 460 1:CAS:528:DC%2BD2sXhvFyru78%3D 17203228
13. KJ Lankester JN Taylor JJ Stirling J Boxall JA d'Arcy DJ Collins, et al. 2007 Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors J Magn Reson Imaging 25 796 805 10.1002/jmri.20881 17347990
14. MO Leach KM Brindle JL Evelhoch JR Griffiths MR Horsman A Jackson, et al. 2005 The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations Br J Cancer 92 1599 1610 10.1038/sj.bjc.6602550 1:CAS:528:DC%2BD2MXjvVansbs%3D 15870830
15. KJ Lankester NJ Taylor JJ Stirling J Boxall JA D'Arcy MO Leach, et al. 2005 Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI Br J Cancer 93 979 985 10.1038/sj.bjc.6602814 1:CAS:528:DC%2BD2MXhtFChsL3P 16234826
16. A Thukral DM Thomasson CK Chow R Eulate SB Wedam SN Gupta, et al. 2007 Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience Radiology 244 727 735 10.1148/radiol.2443060926 17709827
17. S Walker-Samuel CC Parker MO Leach DJ Collins 2007 Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function Phys Med Biol 52 75 89 10.1088/0031-9155/ 52/1/006 1:STN:280:DC%2BD28jksVylsg%3D%3D 17183129
18. RS Benjamin H Choi HA Macapinlac MA Burgess SR Patel LL Chen, et al. 2007 We should desist using RECIST, at least in GIST J Clin Oncol 25 1760 1764 10.1200/JCO.2006.07.3411 17470866
19. Taylor NJ, Tunariu N, Stirling JJ, Collins DJ, Nathan P, d'Arcy JA, et al. Non-enhancing pixels: a specific additional DCE-MRI kinetic parameter for assessing antivascular effects of anti-angiogenic and vascular disruptive agents. Proceedings of the joint meeting of International Society of Magnetic Resonance in Medicine, 16th Scientific Meeting and Exhibition, Honolulu; 2009. p. 2262.
20. HJ Weinmann M Laniado W Mützel 1984 Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers Physiol Chem Phys Med NMR 16 167 172 1:CAS:528:DyaL2cXmt1Kit7c%3D 6505043
21. PS Tofts 1997 Modeling tracer kinetics in dynamic Gd-DTPA MR imaging J Magn Reson Imaging 7 91 101 10.1002/jmri.1880070113 1:STN:280: DyaK2s7ptFKmsA%3D%3D 9039598
22. DL Buckley 2002 Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI Magn Reson Med 47 601 606 10.1002/mrm.10080 11870848
23. CS Landis X Li FW Telang JA Coderre PL Micca WD Rooney, et al. 2000 Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange Magn Reson Med 44 563 574 10.1002/1522-2594(200010)44:4<563::AID-MRM10>3. 0.CO;2-# 1:CAS:528:DC%2BD3cXnsVegtL4%3D 11025512
24. DL Buckley 2002 Transcytolemmal water exchange and its affect on the determination of contrast agent concentration in vivo Magn Reson Med 47 420 424 10.1002/mrm.10098 11810690
25. HP Schlemmer J Merkle R Grobholz T Jaeger MS Michel A Werner, et al. 2004 Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 14 309 317 10.1007/s00330-003-2025-2 14531000
26. AR Padhani A Dzik-Jurasz 2004 Perfusion MR imaging of extracranial tumor angiogenesis Top Magn Reson Imaging 15 41 57 10.1097/00002142-200402000-00005 15057172
27. MC Ferrier H Sarin SH Fung B Schatlo RM Pluta SN Gupta, et al. 2007 Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model Neoplasia 9 546 555 10.1593/neo.07289 1:CAS:528:DC%2BD2sXptlKrtbk%3D 17710157
28. PR Eby SC Partridge SW White RK Doot LK Dunnwald EK Schubert, et al. 2008 Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer Acad Radiol 15 1246 1254 10.1016/j.acra.2008.03.019 18790395
29. KJ Niermann AC Fleischer J Huamani TE Yankeelov DW Kim WD Wilson, et al. 2007 Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography J Ultrasound Med 26 749 756 17526606
30. Conrad C, Friedman H, Reardon D, Provenzale J, Jackson E, Serajuddin H, et al. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol (Meeting Abstracts), 2004. Vol. 22.
31. B Morgan AL Thomas J Drevs J Hennig M Buchert A Jivan, et al. 2003 Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies J Clin Oncol 21 3955 3964 10.1200/JCO.2003.08.092 1:CAS:528:DC%2BD2cXpsVajsbw%3D 14517187
32. K Mross J Drevs M Müller M Medinger D Marmé J Hennig, et al. 2005 Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours Eur J Cancer 41 1291 1299 10.1016/j.ejca.2005.03.005 1:CAS:528:DC%2BD2MXltFCktrc%3D 15939265
33. AL Thomas B Morgan MA Horsfield A Higginson A Kay L Lee, et al. 2005 Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer J Clin Oncol 23 4162 4171 10.1200/JCO.2005.09.034 1:CAS:528:DC%2BD2MXmt1els78%3D 15867205
34. J Drevs M Medinger K Mross U Zirrgiebel R Strecker C Unger, et al. 2005 Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23 3002
35. G Liu HS Rugo G Wilding TM McShane JL Evelhoch C Ng, et al. 2005 Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study J Clin Oncol 23 5464 5473 10.1200/JCO.2005.04.143 1:CAS:528:DC%2BD2MXhtVersr7E 16027440
36. M Medved G Karczmar C Yang J Dignam TF Gajewski H Kindler, et al. 2004 Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: variability and changes in tumor tissue over time J Magn Reson Imaging 20 122 128 10.1002/jmri.20061 15221817
37. A O'Donnell A Padhani C Hayes AJ Kakkar M Leach JM Trigo, et al. 2005 A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points Br J Cancer 93 876 883 10.1038/sj.bjc.6602797 16222321
38. A Dowlati K Robertson T Radivoyevitch J Waas NP Ziats P Hartman, et al. 2005 Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416 Clin Cancer Res 11 7938 7944 10.1158/1078-0432.CCR-04-2538 1:CAS:528:DC%2BD2MXhtF2isLzK 16278419
39. HQ Xiong R Herbst SC Faria C Scholz D Davis EF Jackson, et al. 2004 A phase I surrogate endpoint study of SU6668 in patients with solid tumors Invest New Drugs 22 459 466 10.1023/B:DRUG.0000036688.96453.8d 1:CAS:528: DC%2BD2cXmt1ajsL4%3D 15292716
40. LS Rosen R Kurzrock M Mulay A Van Vugt M Purdom C Ng, et al. 2007 Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors J Clin Oncol 25 2369 2376 10.1200/JCO.2006.07.8170 1:CAS:528:DC%2BD2sXns1KmtL0%3D 17557949
41. GC Jayson J Zweit A Jackson C Mulatero P Julyan M Ranson, et al. 2002 Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies J Natl Cancer Inst 94 1484 1493 1:CAS:528:DC%2BD38XosVans7k%3D 12359857
42. OM Hahn C Yang M Medved G Karczmar E Kistner T Karrison, et al. 2008 Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma J Clin Oncol 26 4572 4578 10.1200/JCO.2007.15.5655 1:CAS:528:DC%2BD1cXht1KqtLfM 18824708
43. KT Flaherty MA Rosen DF Heitjan ML Gallagher B Schwartz MD Schnall, et al. 2008 Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma Cancer Biol Ther 7 496 501 1:CAS:528:DC%2BD1cXhtVSktL%2FJ 18219225
44. AG Sorensen TT Batchelor WT Zhang PJ Chen P Yeo M Wang, et al. 2009 A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res 69 5296 5300 10.1158/0008-5472.CAN-09-0814 1:CAS:528:DC%2BD1MXnvFWqurY%3D 19549889
45. AX Zhu DV Sahani DG Duda E di Tomaso M Ancukiewicz OA Catalano, et al. 2009 Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J Clin Oncol 27 3027 3035 10.1200/JCO.2008.20.9908 1:CAS:528:DC%2BD1MXoslyisb8%3D 19470923
46. SB Wedam JA Low SX Yang CK Chow P Choyke D Danforth, et al. 2006 Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer J Clin Oncol 24 769 777 10.1200/JCO.2005.03.4645 1:CAS:528:DC%2BD28XitVGisbY%3D 16391297
47. B Overmoyer P Silverman R Leeming R Shenk J Lyons N Ziats, et al. 2004 Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22 Abstract 727
48. J Baar P Silverman J Lyons P Fu F Abdul-Karim N Ziats, et al. 2009 A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers Clin Cancer Res 15 3583 3590 10.1158/1078-0432.CCR-08-2917 1:CAS:528: DC%2BD1MXmtVKls7o%3D 19417018
49. SM Galbraith GJ Rustin MA Lodge NJ Taylor JJ Stirling M Jameson, et al. 2002 Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging J Clin Oncol 20 3826 3840 10.1200/JCO.2002.09.144 1:CAS:528: DC%2BD38XntVyns7g%3D 12228202
50. MJ McKeage P Fong M Jeffery BC Baguley P Kestell M Ravic, et al. 2006 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent Clin Cancer Res 12 1776 1784 10.1158/1078-0432.CCR-05-1939 1:CAS:528:DC%2BD28Xis1CjsLw%3D 16551862
51. Evelhoch J, LoRusso P, DelProposto Z, Stark K, Latif Z, Morton P, et al. Dynamic contrast-enhanced MRI evaluation of the effects of ZD6126 on tumor vasculature in a phase I clinical trial, Proc. ISMRM, Honolulu, Hawaii, 2002. Vol. 10.
52. PM LoRusso SM Gadgeel A Wozniak AJ Barge HK Jones ZS DelProposto, et al. 2008 Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors Invest New Drugs 26 159 167 10.1007/s10637-008-9112- 9 1:CAS:528:DC%2BD1cXivFKnsLY%3D 18219445
53. GJ Rustin SM Galbraith H Anderson M Stratford LK Folkes L Sena, et al. 2003 Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results J Clin Oncol 21 2815 2822 10.1200/JCO.2003.05.185 1:CAS:528:DC%2BD2cXpsVKjsLk%3D 12807934
54. SM Galbraith RJ Maxwell MA Lodge GM Tozer J Wilson NJ Taylor, et al. 2003 Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging J Clin Oncol 21 2831 2842 10.1200/JCO.2003.05.187 1:CAS:528:DC%2BD2cXpsVKjsb8%3D 12807936
55. A Dowlati K Robertson M Cooney WP Petros M Stratford J Jesberger, et al. 2002 A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer Cancer Res 62 3408 3416 1:CAS:528:DC%2BD38XkslWqsbw%3D 12067983
56. JP Stevenson M Rosen W Sun M Gallagher DG Haller D Vaughn, et al. 2003 Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow J Clin Oncol 21 4428 4438 10.1200/JCO.2003.12.986 1:CAS:528:DC%2BD2cXpsVajsrk%3D 14645433
57. JH Bilenker KT Flaherty M Rosen L Davis M Gallagher JP Stevenson, et al. 2005 Phase I trial of combretastatin A-4 phosphate with carboplatin Clin Cancer Res 11 1527 1533 10.1158/1078-0432.CCR-04-1434 1:CAS:528:DC%2BD2MXhvVSrsbc%3D 15746056
58. P Nathan I Judson A Padhani A Harris CP Carden J Smythe, et al. 2008 A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors J Clin Oncol 26 3550 10.1200/JCO.2008.16.9607
59. WL Akerley M Schabel G Morrell E Horvath M Yu B Johnsson, et al. 2007 A randomized phase 2 trial of combretastatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25 14060
60. T Meyer AM Gaya G Dancey MR Stratford S Othman SK Sharma, et al. 2009 A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas Clin Cancer Res 15 4484 4492 10.1158/1078-0432.CCR-09-0035 1:CAS:528:DC%2BD1MXnvFajt7o%3D 19549771
61. Y Shaked A Ciarrocchi M Franco CR Lee S Man AM Cheung, et al. 2006 Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313 1785 1787 10.1126/science.1127592 1:CAS:528: DC%2BD28Xpsl2qs74%3D 16990548
62. Padhani AR, Koh DM, Taylor NJ, Stirling JJ, Collins DJ, Rustin GJ, et al. DCE-MRI demonstration of antivascular effects of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to human subjects with advanced solid tumours. Proceedings of the joint meeting of International Society of Magnetic Resonance in Medicine and European Society for Magnetic Resonance in Medicine and Biology 2008:Oral presentation. Program number 773.
63. H Anderson JT Yap P Wells MP Miller D Propper P Price, et al. 2003 Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane Br J Cancer 89 262 267 10.1038/sj.bjc.6601105 1:CAS:528:DC%2BD3sXlsVaktbc%3D 12865914
64. GC Jayson GJ Parker S Mullamitha JW Valle M Saunders L Broughton, et al. 2005 Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume J Clin Oncol 23 973 981 10.1200/JCO.2005.01.032 1:CAS:528:DC%2BD2MXit1Gnsr4%3D 15466784
65. AR Padhani NJ Taylor JA d'Arcy S Walker-Samuel DJ Collins B Knowles, et al. 2006 Dynamic MRI evaluation of the triple receptor tyrosine kinase inhibitor BIBF 1120 in patients with advanced solid tumours Proc Int Soc Magn Reson Med 14 765
66. R Strecker K Mross M Stefanic L de Rossi J Hennig 2006 Evaluation of the effects of the triple angiokinase inhibitor BIBF 1120 on tumor vasculature in a phase I clinical trial using dynamic contrast-enhanced MRI (DCE-MRI) Proc Int Soc Magn Reson Med 14 764
67. DJ Jonker LS Rosen M Sawyer G Wilding C Noberasco G Jayson, et al. 2007 A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25 Abstract 3559
68. NCI. Recommendations for MR measurement methods at 1.5-Tesla and endpoints for use in Phase 1/2a trials of anti-cancer therapeutics affecting tumor vascular function. http://imaging.cancer.gov/images/Documents/14a39040- dad1-46f8-bf88-bae2e7401ebe/DCE-RecommendationfromNov2004NCIWorkshop(2).pdf, 2004.
69. MO Leach KM Brindle JL Evelhoch JR Griffiths MR Horsman A Jackson, et al. 2005 The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations Br J Cancer 92 1599 1610 10.1038/sj.bjc.6602550 1:CAS:528:DC%2BD2MXjvVansbs%3D 15870830
70. J Evelhoch M Garwood D Vigneron M Knopp D Sullivan A Menkens, et al. 2005 Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report Cancer Res 65 7041 7044 10.1158/0008-5472.CAN-05-0674 1:CAS:528:DC%2BD2MXns1Wrt7k%3D 16103049
71. CG Willett Y Boucher E di Tomaso DG Duda LL Munn RT Tong, et al. 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145 147 10.1038/nm988 1:CAS:528:DC%2BD2cXoslKmtQ%3D%3D 14745444
72. RS Herbst NA Mullani DW Davis KR Hess DJ McConkey C Charnsangavej, et al. 2002 Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin J Clin Oncol 20 3804 3814 10.1200/JCO.2002.05.102 1:CAS:528:DC%2BD38XntVyns7o%3D 12228200
73. S Loges M Mazzone P Hohensinner P Carmeliet 2009 Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited Cancer Cell 15 167 170 10.1016/j.ccr.2009.02.007 1:CAS:528:DC%2BD1MXltFSmtb0%3D 19249675
74. DM Patterson AR Padhani DJ Collins 2008 Technology insight: water diffusion MRI-a potential new biomarker of response to cancer therapy Nat Clin Pract Oncol 5 220 233 10.1038/ncponc1073 18301415
75. PJ O'Dwyer M Rosen M Gallagher B Schwartz KT Flaherty 2005 Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma J Clin Oncol (Meeting Abstracts) 23 3005
76. LS Rosen G Wilding C Sweeney D Casale G Kollia C Wu, et al. 2006 Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors J Clin Oncol (Meeting Abstracts) 24 3051
77. Mross KB, Gmehling D, Frost A, Baas F, Strecker R, Hennig J, et al. A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients. J Clin Oncol (Meeting Abstracts), 2005. Vol. 23.
78. JP Eder Jr JG Supko JW Clark TA Puchalski R Garcia-Carbonero DP Ryan, et al. 2002 Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily J Clin Oncol 20 3772 3784 10.1200/JCO.2002.02.082 1:CAS:528:DC%2BD38XntVyns7w%3D 12228197
79. JP Thomas RZ Arzoomanian D Alberti R Marnocha F Lee A Friedl, et al. 2003 Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors J Clin Oncol 21 223 231 10.1200/JCO.2003.12.120 1:CAS:528:DC%2BD2cXpsVWqsrc%3D 12525513
80. Y Watson S Cheung C Roberts G Buonaccorsi K Davies A Jackson, et al. 2006 Prognostic power of DCE-MRI heterogeneity analysis in patients with advanced solid tumors Proc Int Soc Magn Reson Med 14 755
81. A Perotti C Sessa A Mancuso C Noberasco S Cresta A Locatelli, et al. 2009 Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours Ann Oncol 20 741 745 10.1093/annonc/mdn695 1:STN:280:DC%2BD1M3jt1Gjtw%3D%3D 19190075
82. DM Patterson N Charnley A Saleem M Stratford C Dickinson M Asselin, et al. 2008 Phase I evaluation of vascular disrupting agent OXi4503 J Clin Oncol 26 Abstract 3551
83. JL Evelhoch PM LoRusso Z He Z DelProposto L Polin TH Corbett, et al. 2004 Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126 Clin Cancer Res 10 3650 3657 10.1158/1078-0432.CCR-03-0417 1:CAS:528:DC%2BD2cXksVKnsbo%3D 15173071